Kaleo Logo

News

Media Contact

media.inquiries@kaleo.com

Person working on laptop

News Archive

May 14, 2025

Retrospective Analysis of U.S. Claims Data Shows AUVI-Q® (epinephrine injection, USP) Prescription Associated with Lower Rates of Anaphylaxis-Related Inpatient Hospitalizations Compared to Other Epinephrine Auto-Injectors
April 23, 2025

National Organizations Unite to Prepare Early Childcare Facilities for Rising Incidence of Food Allergies
October 28, 2024

Kaléo Announces Chief Development Officer
October 1, 2024

Kaléo Redesigns Commercial Team to Increase Support for AUVI-Q® (epinephrine injection, USP)
April 16, 2024

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure
July 18, 2023

U.S. Department of Defense Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure
June 26, 2023

Kaléo Expands Executive Team to Support Growth
April 4, 2023

Kaléo Welcomes Vice President, Marketing and Analytics Executive
December 12, 2022

Kaléo and Parexel Win Quality Award from the Abstract Committee of the American Conference on Pharmacometrics
October 25, 2022

Kaléo Announces Appointment of Major General Elder Granger, M.D., to Board 
September 27, 2022

Kaléo Adds Chief Business Officer to Executive Team
September 21, 2022

Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids
September 13, 2022

Rapid Opioid Countermeasure System Product Team Wins Award for Outstanding Program Management Team at 2022 Military Health System Research Symposium
August 11, 2022

Kaléo Announces Executive Appointments and New Government Business Unit 
August 2, 2022

Kaléo Enters Into Licensing Agreement With Valeo Pharma For The Canadian Rights to ALLERJECT®(epinephrine injection, USP)
May 8, 2022

Caring for the Caregiver
March 2, 2022

FDA Approves Kaléo’s Naloxone Auto-Injector 10 mg for the Treatment of Known or Potential Exposure to Ultra-Potent Weaponized Opioids
November 29, 2021

Marathon Asset Management Announces Acquisition of Kaléo
1 2 3 4